We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

106 hedge funds and large institutions have $186M invested in Cymabay Therapeutics in 2022 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 30 increasing their positions, 32 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more call options, than puts

Call options by funds: $801K | Put options by funds: $345K

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

6% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 32

10% less funds holding

Funds holding: 118 → 106 (-12)

13% less capital invested

Capital invested by funds: $213M → $186M (-$27.1M)

29% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 28

Holders
106
Holders Change
-12
Holders Change %
-10.17%
% of All Funds
1.79%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
20
Increased
30
Reduced
32
Closed
28
Calls
$801K
Puts
$345K
Net Calls
+$456K
Net Calls Change
+$107K

Top Buyers

Rank Fund Capital Flow
1
LCM
Laurion Capital Management
New York
+$3.76M
2
LCM
Lynx1 Capital Management
Puerto Rico
+$2.87M
3
NCM
Nantahala Capital Management
Connecticut
+$1.79M
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$1.71M
5
Millennium Management
Millennium Management
New York
+$1.54M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$8.39M
2
JP Morgan Chase
JP Morgan Chase
New York
-$3.11M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$2.39M
4
State Street
State Street
Massachusetts
-$2.38M
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$1.44M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
26
UBS Group
Switzerland
$1.34M +$1.01M +423,806 +1,347%
E
27
Ergoteles
New York
$1.21M +$980K +410,400 New
HS
28
HighVista Strategies
Massachusetts
$1.17M +$449K +188,025 +91%
State Street
29
State Street
Massachusetts
$1.07M -$2.38M -995,930 -73%
Point72 Asset Management
30
Point72 Asset Management
Connecticut
$1.03M +$836K +350,000 New
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$782K -$107K -44,941 -14%
FI
32
Fosun International
China
$778K – – –
Citigroup
33
Citigroup
New York
$774K +$614K +256,894 +4,662%
Goldman Sachs
34
Goldman Sachs
New York
$753K -$738K -309,073 -55%
PCM
35
Pinz Capital Management
New York
$683K +$553K +231,680 New
Invesco
36
Invesco
Georgia
$664K +$6.59K +2,759 +1%
Rockefeller Capital Management
37
Rockefeller Capital Management
New York
$631K -$31.5K -13,175 -6%
CM
38
CM Management
Florida
$620K +$143K +60,000 +40%
AGM
39
Alpine Global Management
New York
$584K -$124K -52,112 -21%
Two Sigma Advisers
40
Two Sigma Advisers
New York
$435K +$49K +20,500 +16%
Connor, Clark & Lunn Investment Management (CC&L)
41
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$430K +$188K +78,692 +117%
Northern Trust
42
Northern Trust
Illinois
$410K -$1.42M -592,728 -81%
Barclays
43
Barclays
United Kingdom
$398K +$222K +93,054 +222%
CAM
44
ClariVest Asset Management
California
$392K – – –
A
45
Abingworth
United Kingdom
$385K – – –
Deutsche Bank
46
Deutsche Bank
Germany
$375K -$89.6K -37,507 -23%
Bank of America
47
Bank of America
North Carolina
$365K +$118K +49,333 +66%
T. Rowe Price Associates
48
T. Rowe Price Associates
Maryland
$360K +$28.8K +12,077 +11%
Two Sigma Investments
49
Two Sigma Investments
New York
$333K +$65.7K +27,496 +32%
CANY
50
Caxton Associates (New York)
New York
$310K -$30.3K -12,700 -11%
1
2
3 4 5

CBAY Hedge Fund Activity: Q2 2022 in Review

106 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q2 2022, worth a combined $186M — down 13% from $213M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of CBAY and 20 opened new positions — a net loss of 8 holders — while 32 trimmed existing stakes and 30 added.

The largest buyer was Laurion Capital Management, opening a new position worth an estimated $3.76M. The largest seller was BlackRock, cutting an estimated $8.39M.

  • 106 institutional investors held Cymabay Therapeutics (CBAY) as of Q2 2022, down from 118 in Q1 2022.
  • Funds reported $186M of Cymabay Therapeutics stock for Q2 2022, down 13% quarter-over-quarter.
  • 20 funds opened new Cymabay Therapeutics positions in Q2 2022 and 28 closed out, a net change of -8 holders.
  • The largest Cymabay Therapeutics buyer in Q2 2022 was Laurion Capital Management, an estimated $3.76M added.
  • The largest Cymabay Therapeutics seller in Q2 2022 was BlackRock, an estimated $8.39M sold.

Based on aggregated 13F filings for Q2 2022.